睿知中国医院研究地图
候选清单

正在招募淋巴瘤早期I期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

Targeting CD5 CAR-T Cells in the Treatment of r/r CD5+ T-lymphoma

ClinicalTrials.gov 上登记的一项淋巴瘤开放试验,由浙江大学医学院附属第一医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)浙江大学医学院附属第一医院First Affiliated Hospital, Zhejiang University杭州医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT06633341,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 6

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(6 项)收起清单
  1. 1. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),

    入选标准第 1 条

  2. 6. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:

    排除标准第 6 条

    received within 72 hours of small molecule targeted therapy;

    排除标准第 8 条

    2 weeks received systemic chemotherapy except (pretreatment);

    排除标准第 9 条

  3. 8. ECOG 0-2;

    入选标准第 11 条

  4. 4. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);

    入选标准第 7 条

  5. 3. Active infection of hepatitis B virus, C virus or hepatitis E virus;

    排除标准第 3 条

  6. 9. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;

    入选标准第 12 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:分期或严重程度(按试验的定义);影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT06633341,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. 1. According to the 2016 WHO classification of lymphocyte tumors, histologically confirmed CD5-positive T-cell non-Hodgkin lymphoma (T-NHL),
  2. Subjects did not go into remission or relapse after receiving second-line or more chemotherapy regiments;
  3. Primary drug resistance;
  4. Relapse after autologous hematopoietic stem cell transplantation;
  5. 2.CD5 expression rate was >90%;
  6. 3. According to Lugano 2014, there should be at least one evaluable tumor lesion;
  7. 4. Total bilirubin ≤51 (mol/L), Alanine aminotransferase (ALT)/Aspartate aminotransferase (AST) ≤ 3 times the upper limit of the normal range, creatinine ≤176.8 (mol/L);
  8. 5. Echocardiography showed left ventricular ejection fraction (LVEF) ≥50%;
  9. 6. Refers to the pulse oxygen saturation 92% or higher oxygen (state);
  10. 7. Estimated life expectancy of minimum of 12 weeks;
  11. 8. ECOG 0-2;
  12. 9. Pregnant/lactating women, or male or female patients who have fertility and are willing to take effective contraceptive measures at least 6 months after the last cell infusion during the study period;
  13. 10. Those who voluntarily participated in this trial and provided informed consent;

排除标准:Exclusion Criteria:

  1. 1. History of epilepsy or other central nervous system disorders;
  2. 2. Electrocardiogram shows prolonged QT interval, severe heart diseases such as severe arrhythmia in the past;
  3. 3. Active infection of hepatitis B virus, C virus or hepatitis E virus;
  4. 4. Active infected persons who are not cured;
  5. 5. Before using any gene therapy products;
  6. 6. Received anti-tumor therapy before infusion, should meet the following any one should be ruled out:
  7. treated with systemic corticosteroids therapy within 72 hours (except glucocorticoid physiological replacement therapy, such as prednisone < 10 mg/d or an equivalent dose of the drug);
  8. received within 72 hours of small molecule targeted therapy;
  9. 2 weeks received systemic chemotherapy except (pretreatment);
  10. four weeks received radiotherapy;
  11. 7. The proiferation rate is less than 5 times response to CD3/CD28 co-stimulation signal;
  12. 8. Any unsuitable to participate in this trial judged by the investigator;
  13. 9. Any situation that researchers believe may increase the risk to the subjects or interfere with the trial results.

引自 ClinicalTrials.gov, NCT06633341, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT06633341,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT06633341